吉祥坊登录

Beijing, China – On April 1, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the 2017 Vascular Innovative Forum. The forum was hosted by the Vascular Device Branch of China Association for Medical Device Industry and the Special Committee of Vascular Medicine of Chinese Research Hospital Association, and organized by the Vascular Surgery Department of Chinese PLA General Hospital. The forum aims to provide a platform for clinical experts, policy makers, industry peers, and investors to exchange ideas on the cutting-edge technology and evidence-based medicine research related to the field of vascular diseases.

This forum primarily focused on medico-engineering cooperation, big-data medicine, new technology and new material, clinical needs, data management and statistical analysis, innovation demonstration, government policy and the Green-Path fast-track review and approval procedure, and protection of patent and intellectual property related to the field of vascular diseases. During the forum, Professor Rui Feng of Shanghai Changhai Hospital of the Second Military Medical University presented the innovation path of China's endovascology. When talking about how to bring forth new ideas in old practice, Professor Feng took MicroPort® Endovascular's Castor™ Branched Aortic Stent Graft and delivery system ("Castor™") as an example. He said, Castor™ is the first international successful transformation on the aortic arch branched endo-stent-graft, marking a significant step forward in using the technology of aortic arch endovascular intervention to treat aortic arch. As the world's first stent system for simultaneous reconstruction of the aorta and the aortic arch branches, Castor™ uses unique unibody branch design and unique double-approach delivery design: unibody branch design ensures stent graft integrity and low porosity graft material significantly lowers endoleak of Type IV. In addition, the double-approach delivery, the branch guiding wire technique and the trigger wire design also provide elaborate, accurate and safe experience to the operator.

In the forum, MicroPort® Chief Technology Officer Dr. Qiyi Luo delivered a speech of "building a sustainable medical device innovative platform" in which he pointed out: "Innovation is the lifeline for the company's sustainable development and a strategy as well." Shanghai MicroPort® Medical (Group) Co., Ltd. ("MicroPort®") has built the innovation program and innovation platform and developed several medical devices that lead in the world, successfully transforming our product offering from a market follower to a leader in some segments, which will serve as an experience for other domestic medical device developers. Up to date, eight products in-house developed by MicroPort® and its subsidiaries entered to the fast-track review and approval procedure of China Food and Drug Administration ("CFDA") and two of them gained the CFDA approval. In the future, MicroPort® and its subsidiaries will continue to innovate to provide patients with high-quality and affordable medical solutions that save and reshape lives or improve life quality.